Take SHPT treatment in a different direction

Treating secondary hyperparathyroidism
Rayaldee® (calcifediol) is the first and only extended-release prohormone of the active form of vitamin D3 that brings 25-hydroxyvitamin D [25(OH)D] levels up, brings intact parathyroid hormone (iPTH) levels down, and has effects on calcium and phosphorus that are similar to those of placebo in adults with secondary hyperparathyroidism (SHPT) with stage 3 or 4 chronic kidney disease (CKD) and low vitamin D levels.*1,2
* | Calcium: Rayaldee 0.2 (0.02) mg/dL versus placebo 0.1 (0.03) mg/dL (P<0.001); Phosphorus: Rayaldee 0.2 (0.03) mg/dL versus placebo 0.1 (0.04) mg/dL1 |


Clinical trial highlights
In the clinical trials, significantly more adults achieved reduction in iPTH by ≥30% from baseline and increase in 25(OH)D to adequate levels (versus placebo; P<0.001)2
• | Increased serum 25(OH)D levels were associated with corresponding increases in serum 1,25D levels2 |
• | Serum iPTH levels declined over time with Rayaldee compared to placebo treatment (P<0.001)2 |
• | The effect of Rayaldee on serum levels of calcium and phosphorus was similar to that of placebo*1 |
* | Calcium: Rayaldee 0.2 (0.02) mg/dL versus placebo 0.1 (0.03) mg/dL (P<0.001); Phosphorus: Rayaldee 0.2 (0.03) mg/dL versus placebo 0.1 (0.04) mg/dL1 |


Comprehensive support for your patients
Access matters. That’s why OPKO Connect was created. OPKO Connect is more than a patient assistance program. OPKO Connect can also help with prior authorizations for Rayaldee. Additionally, through OPKO Connect, patients can speak with pharmacists and general support experts to better understand Rayaldee and SHPT.

References: 1. Rayaldee [package insert]. Miami, FL: OPKO Pharmaceuticals, LLC; December 2019. 2. Sprague SM, Crawford PW, Melnick JZ, et al. Use of extended-release calcifediol to treat secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Am J Nephrol. 2016;44(4):316-325.